An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1922-1930

  Nassar, Alaa Eldin F ^a   King, Ivan ^a   Paris, Brandy L ^b   Haupt, Lois ^b   Ndikum Moffor, Florence ^b   Campbell, Rebecca ^b   Usuki, Etsuko ^b   Skibbe, Jennifer ^b   Brobst, Dan ^b   Ogilvie, Brian W ^b   Parkinson, Andrew ^b  

^a Vion Pharmaceuticals Incorporated   (United States)

^b XenoTech LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLORETAZINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG DECOMPOSITION; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREACTIVITY; IN VITRO STUDY; LIVER CELL CULTURE; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MONKEY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; ENZYME INDUCTION; HAPLORHINI; HUMANS; HYDRAZINES; HYDROXYLATION; ISOENZYMES; MICROSOMES, LIVER; NADP; PHENOTYPE; RATS; SULFONAMIDES;

CANIS FAMILIARIS; RATTUS;

EID: 70349100116     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027516     Document Type: Article

References (19)

1. Arlotto MP, Greenway DJ, and Parkinson A (1989) Purification of two isozymes of rat liver microsomal cytochrome P-450 with testosterone 7α-hydroxylase activity. Arch Biochem Biophys 270:441-457. (Pubitemid 19109019)
2. Baumann RP, Seow HA, Shyam K, Penketh PG, and Sartorelli AC (2005) The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res 15:313-325. (Pubitemid 43074226)
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832. (Pubitemid 36759050)
4. Finch RA, Shyam K, Penketh PG, and Sartorelli AC (2001) 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-(methylamino)-carbonylhydrazine (101M): a novel sulfonyl-hydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 61:3033-3038. (Pubitemid 32691951)
5. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, et al. (2004) A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10:2908-2917. (Pubitemid 38619664)
6. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670. (Pubitemid 351713150)
7. Jones DR, Ekins S, Li L, and Hall SD (2007) Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos 35:1466-1475. (Pubitemid 47296037)
8. KITZ R and WILSON IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
9. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227:680-685.
10. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 (CYP) expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431. (Pubitemid 36378519)
11. Nassar AE, Talaat RE, and Tokuno H (2007) Drug interactions: concerns and current approaches. IDrugs 10:47-52.
12. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197. (Pubitemid 43042661)
13. Ogilvie BW, Usuki E, Yerino P, and Parkinson A (2008) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450, in Drug-Drug Interactions: Drugs and the Pharmaceutical Sciences, 2nd ed (Rodrigues AD ed) pp 231-358, Informa Healthcare, New York.
14. Parkinson A and Ogilvie BW (2008) Biotransformation of xenobiotics, in Casarett & Doull's Toxicology: The Basic Science of Poisons, 7th ed (Klaassen CD, ed) pp 161-304, McGraw-Hill, New York.
15. Penketh PG, Shyam K, and Sartorelli AC (2000) Comparison of DNA lesions produced by tumor inhibitory 1,2-bis(sulfonyl)-hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 59:283-291. (Pubitemid 30001755)
16. Penketh PG, Shyam K, Baumann RP, Remack JS, Brent TP, and Sartorelli AC (2004) 1,2- Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl] hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 53:279-287. (Pubitemid 38392352)
17. Robertson P, DeCory HH, Madan A, and Parkinson A (2000) In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28:664-671. (Pubitemid 30390406)
18. Towbin H, Staehelin T, and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc Natl Acad Sci U S A 76:4350-4354. (Pubitemid 9256559)
19. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 18:1071-1080. (Pubitemid 32900389)